Barinthus Biotherapeutics PLCNASDAQ:BRNS
- LAST PRICE0.9649
- TODAY'S CHANGE (%)0.0701 (7.8406%)
- Bid / Lots0.9500/ 15
- Ask / Lots0.9797/ 7
- Open / Previous Close0.9340 / 0.8947
- Day Range
- 52 Week Range
- Volume163,504
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BRNS |
|---|---|---|
| 09:32 ET | 4329 | 0.9724 |
| 09:33 ET | 67500 | 0.9 |
| 09:35 ET | 54600 | 0.9 |
| 09:37 ET | 283 | 1.04 |
| 09:42 ET | 203 | 0.9005 |
| 10:09 ET | 499 | 0.9301 |
| 10:36 ET | 3422 | 0.9401 |
| 11:09 ET | 316 | 0.9602 |
| 11:39 ET | 4050 | 1.0099 |
| 11:54 ET | 500 | 0.9876 |
| 12:01 ET | 801 | 0.9999 |
| 12:03 ET | 107 | 1 |
| 12:21 ET | 200 | 1 |
| 12:42 ET | 400 | 0.9751 |
| 12:46 ET | 400 | 1 |
| 12:50 ET | 1466 | 0.9998 |
| 12:51 ET | 1579 | 0.9999 |
| 12:57 ET | 9870 | 1 |
| 01:00 ET | 1328 | 1.01 |
| 01:02 ET | 4242 | 1.02 |
| 01:26 ET | 110 | 0.95 |
| 01:36 ET | 316 | 0.96485 |
| 01:56 ET | 572 | 0.95 |
| 02:39 ET | 900 | 0.9615 |
| 03:03 ET | 597 | 0.9611 |
| 03:10 ET | 911 | 0.9591 |
| 03:14 ET | 330 | 0.9556 |
| 03:15 ET | 1100 | 0.9649 |
| 03:17 ET | 100 | 0.96485 |
Nov 19, 2024
DJ Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co., from 4:39AM ET on Tuesday Nov 19, 2024 by Dow Jones
4:39AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 15, 2024
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion, from 11:02AM ET on Friday Nov 15, 2024 by Dow Jones
11:02AM ET on Friday Nov 15, 2024 by Dow JonesArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B, from 11:01AM ET on Friday Nov 15, 2024 by Dow Jones
11:01AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 8, 2024
DJ Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co., from 2:09PM ET on Friday Nov 08, 2024 by Dow Jones
2:09PM ET on Friday Nov 08, 2024 by Dow Jones
Nov 6, 2024
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Barinthus Biotherapeutics PLC | 36.0M | -0.6x | --- |
Elevation Oncology Inc | 35.7M | -0.8x | --- |
Intensity Therapeutics Inc | 35.5M | -2.6x | --- |
Clene Inc. | 31.6M | -0.8x | --- |
CEL-SCI Corp | 36.6M | -1.1x | --- |
Calidi Biotherapeutics Inc | 37.5M | -0.4x | --- |
Company Information
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.
Contact Information
- Headquarters
- The Schrdinger Building Heatley Road, The Oxford Science ParkDIDCOT, United Kingdom OX11 0DF
- Phone
- 186-581-8808
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Robin Wright
- Chief Executive Officer, Director
- William Enright
- Chief Financial Officer, Company Secretary
- Gemma Brown
- Chief Operating Officer
- Graham Griffiths
- Chief Scientific Officer
- Nadege Pelletier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.0M |
|---|---|
Revenue (TTM) | $15.0M |
Shares Outstanding | 40.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.71 |
EPS | $-1.49 |
Book Value | $4.83 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 2.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -431.34% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
